Log In
Print
BCIQ
Print
Print this Print this
 

Complera, Eviplera, emtricitabine/tenofovir/rilpivirine

Also known as: Truvada TMC278 combination

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination of the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine
Molecular Target HIV reverse transcriptase
Mechanism of ActionHIV reverse transcriptase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infection
Regulatory Designation

U.S. - Priority Review (Treat HIV-1 infection)

Partner

Johnson & Johnson


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today